{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:22:33Z","timestamp":1766514153951},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,12,21]],"date-time":"2019-12-21T00:00:00Z","timestamp":1576886400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,21]],"date-time":"2019-12-21T00:00:00Z","timestamp":1576886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s00380-019-01543-6","type":"journal-article","created":{"date-parts":[[2019,12,21]],"date-time":"2019-12-21T18:02:46Z","timestamp":1576951366000},"page":"776-785","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparing the effects of milrinone and olprinone in patients with congestive heart failure"],"prefix":"10.1007","volume":"35","author":[{"given":"Shintaro","family":"Dobashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ippei","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rine","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Hisatake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Kiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Kabuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,21]]},"reference":[{"key":"1543_CR1","doi-asserted-by":"publisher","first-page":"29060","DOI":"10.3390\/ijms161226147","volume":"16","author":"S Tariq","year":"2015","unstructured":"Tariq S, Aronow WS (2015) Use of inotropic agents in treatment of systolic heart failure. Int J Mol Sci 16:29060\u201329068","journal-title":"Int J Mol Sci"},{"key":"1543_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jacc.2005.04.007","volume":"46","author":"GW Dec","year":"2005","unstructured":"Dec GW (2005) Acute decompensated heart failure: the shrinking role of inotropic therapy. J Am Coll Cardiol 46:65\u201367","journal-title":"J Am Coll Cardiol"},{"key":"1543_CR3","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/0002-9149(87)90616-3","volume":"60","author":"EJ Eichhorn","year":"1987","unstructured":"Eichhorn EJ, Konstam MA, Weiland DS, Roberts DJ, Martin TT, Stransky NB, Salem DN (1987) Differential effects of milrinone and dobutamine on right ventricular preload, afterload and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 60:1329\u20131333","journal-title":"Am J Cardiol"},{"key":"1543_CR4","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/0002-8703(91)90834-5","volume":"121","author":"G Mager","year":"1991","unstructured":"Mager G, Klocke RK, Kux A, Hopp HW, Hilger HH (1991) Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure. Am Heart J 121:1974\u20131983","journal-title":"Am Heart J"},{"key":"1543_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1527-3466.2002.tb00085.x","volume":"20","author":"K Mizushige","year":"2002","unstructured":"Mizushige K, Ueda T, Yukiiri K, Suzuki H (2002) Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev 20:163\u2013174","journal-title":"Cardiovasc Drug Rev"},{"key":"1543_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/00005344-200003000-00012","volume":"35","author":"Y Yu","year":"2000","unstructured":"Yu Y, Mizushige K, Ueda T, Nishiyama Y, Seki M, Aoyama T, Ohkawa M, Matsuo H (2000) Effect of olprinone, phosphodiesterase III inhibitor, on cerebral blood flow assessed with technetium-99m-ECD SPECT. J Cardiovasc Pharmacol 35:422\u2013426","journal-title":"J Cardiovasc Pharmacol"},{"key":"1543_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/00005344-200104000-00004","volume":"37","author":"K Yukiiri","year":"2001","unstructured":"Yukiiri K, Mizushige K, Ueda T, Nishiyama Y, Aoyama T, Kohno M (2001) Effects of olprinone, a phosphodiesterase 3 inhibitor, on regional cerebral blood flow of cerebral cortex in stroke patients. J Cardiovasc Pharmacol 37:375\u2013380","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1274\u20131277","key":"1543_CR8","first-page":"A9","volume":"83","author":"M Kanda","year":"1999","unstructured":"Kanda M, Yasuda S, Goto Y, Sumida H, Baba T, Noguchi T, Nonogi H (1999) Diuretic effect of phosphodiesterase inhibitors depends on baseline renal function in patients with congestive heart failure. Am J Cardiol 83(1274\u20131277):A9","journal-title":"Am J Cardiol"},{"key":"1543_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1442-2042.2007.01689.x","volume":"14","author":"C Anas","year":"2007","unstructured":"Anas C, Ozaki T, Maruyama S, Yamamoto T, Zu Gotoh M, Ono Y, Matsuo S (2007) Effects of olprinone, a phosphodiesterase III inhibitor, on ischemic acute renal failure. Int J Urol 14:219\u2013225","journal-title":"Int J Urol"},{"key":"1543_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.phrs.2010.12.010","volume":"64","author":"E Mazzon","year":"2011","unstructured":"Mazzon E, Esposito E, Di Paola R, Impellizzeri D, Bramanti P, Cuzzocrea S (2011) Olprinone, a specific phosphodiesterase (PDE)-III inhibitor, reduces the development of multiple organ dysfunction syndrome in mice. Pharmacol Res 64:68\u201379","journal-title":"Pharmacol Res"},{"key":"1543_CR11","first-page":"1580","volume":"46","author":"K Okuda","year":"1997","unstructured":"Okuda K, Kudo H, Ohishi K, Kitano T, Imasaka H, Noguchi T (1997) Effects of olprinone on IL-6 and IL-10 production during and after cardiac surgery. Masui 46:1580\u20131584","journal-title":"Masui"},{"key":"1543_CR12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s00540-006-0485-7","volume":"21","author":"S Tosaka","year":"2007","unstructured":"Tosaka S, Makita T, Tosaka R, Maekawa T, Cho S, Hara T, Ureshino H, Sumikawa K (2007) Cardioprotection induced by olprinone, a phosphodiesterase III inhibitor, involves phosphatidylinositol-3-OH kinase-Akt and a mitochondrial permeability transition pore during early reperfusion. J Anesth 21:176\u2013180","journal-title":"J Anesth"},{"key":"1543_CR13","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","volume":"287","author":"MS Cuffe","year":"2002","unstructured":"Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M (2002) Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure I. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287:1541\u20131547","journal-title":"JAMA"},{"key":"1543_CR14","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S0735-1097(02)02968-6","volume":"41","author":"GM Felker","year":"2003","unstructured":"Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, Gheorghiade M, O'Connor CM, Investigators O-C (2003) Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 41:997\u20131003","journal-title":"J Am Coll Cardiol"},{"key":"1543_CR15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S0008-6363(99)00370-3","volume":"45","author":"K Singh","year":"2000","unstructured":"Singh K, Communal C, Sawyer DB, Colucci WS (2000) Adrenergic regulation of myocardial apoptosis. Cardiovasc Res 45:713\u2013719","journal-title":"Cardiovasc Res"},{"key":"1543_CR16","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S0002-8703(96)90236-7","volume":"132","author":"C Indolfi","year":"1996","unstructured":"Indolfi C, Piscione F, Perrone-Filardi P, Prastaro M, Di Lorenzo E, Sacca L, Salvatore M, Condorelli M, Chiariello M (1996) Inotropic stimulation by dobutamine increases left ventricular regional function at the expense of metabolism in hibernating myocardium. Am Heart J 132:542\u2013549","journal-title":"Am Heart J"},{"key":"1543_CR17","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1161\/01.RES.70.6.1282","volume":"70","author":"R Schulz","year":"1992","unstructured":"Schulz R, Guth BD, Pieper K, Martin C, Heusch G (1992) Recruitment of an inotropic reserve in moderately ischemic myocardium at the expense of metabolic recovery. A model of short-term hibernation. Circ Res 70:1282\u20131295","journal-title":"Circ Res"},{"key":"1543_CR18","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1161\/01.CIR.97.18.1848","volume":"97","author":"RA Kloner","year":"1998","unstructured":"Kloner RA, Bolli R, Marban E, Reinlib L, Braunwald E (1998) Medical and cellular implications of stunning, hibernation, and preconditioning: an NHLBI workshop. Circulation 97:1848\u20131867","journal-title":"Circulation"},{"key":"1543_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1177\/0003319713485808","volume":"65","author":"D Charisopoulou","year":"2014","unstructured":"Charisopoulou D, Leaver N, Banner NR (2014) Milrinone in advanced heart failure: dose and therapeutic monitor outside intensive care unit. Angiology 65:343\u2013349","journal-title":"Angiology"},{"key":"1543_CR20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1177\/1074248413489773","volume":"18","author":"ZL Cox","year":"2013","unstructured":"Cox ZL, Calcutt MW, Morrison TB, Akers WS, Davis MB, Lenihan DJ (2013) Elevation of plasma milrinone concentrations in stage D heart failure associated with renal dysfunction. J Cardiovasc Pharmacol Ther 18:433\u2013438","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"1543_CR21","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/S0140-6736(05)74356-7","volume":"353","author":"GA Drummond","year":"1999","unstructured":"Drummond GA, Squire IB (1999) The cardiac insufficiency bisoprolol study II. Lancet 353:1361","journal-title":"Lancet"},{"key":"1543_CR22","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0002-8703(99)70405-9","volume":"137","author":"M Gardtman","year":"1999","unstructured":"Gardtman M, Dellborg M, Brunnhage C, Lindkvist J, Waagstein L, Herlitz J (1999) Effect of intravenous metoprolol before hospital admission on chest pain in suspected acute myocardial infarction. Am Heart J 137:821\u2013829","journal-title":"Am Heart J"},{"key":"1543_CR23","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","volume":"357","author":"HJ Dargie","year":"2001","unstructured":"Dargie HJ (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357:1385\u20131390","journal-title":"Lancet"},{"key":"1543_CR24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1067\/mhj.2001.117318","volume":"142","author":"JA Joglar","year":"2001","unstructured":"Joglar JA, Acusta AP, Shusterman NH, Ramaswamy K, Kowal RC, Barbera SJ, Hamdan MH, Page RL (2001) Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 142:498\u2013501","journal-title":"Am Heart J"},{"key":"1543_CR25","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S0735-1097(02)02134-4","volume":"40","author":"M Metra","year":"2002","unstructured":"Metra M, Nodari S, D'Aloia A, Muneretto C, Robertson AD, Bristow MR, Dei Cas L (2002) Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 40:1248\u20131258","journal-title":"J Am Coll Cardiol"},{"key":"1543_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0167-5273(01)00520-4","volume":"81","author":"BD Lowes","year":"2001","unstructured":"Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR (2001) Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol 81:141\u2013149","journal-title":"Int J Cardiol"},{"key":"1543_CR27","first-page":"109","volume":"30","author":"AM Zewail","year":"2003","unstructured":"Zewail AM, Nawar M, Vrtovec B, Eastwood C, Kar MN, Delgado RM 3rd (2003) Intravenous milrinone in treatment of advanced congestive heart failure. Tex Heart Inst J 30:109\u2013113","journal-title":"Tex Heart Inst J"},{"key":"1543_CR28","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1067\/mhj.2001.117605","volume":"142","author":"A Kumar","year":"2001","unstructured":"Kumar A, Choudhary G, Antonio C, Just V, Jain A, Heaney L, Papp MA (2001) Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. Am Heart J 142:512\u2013515","journal-title":"Am Heart J"},{"key":"1543_CR29","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1592\/phco.27.5.697","volume":"27","author":"GL Earl","year":"2007","unstructured":"Earl GL, Verbos-Kazanas MA, Fitzpatrick JM, Narula J (2007) Tolerability of beta-blockers in outpatients with refractory heart failure who were receiving continuous milrinone. Pharmacotherapy 27:697\u2013706","journal-title":"Pharmacotherapy"},{"key":"1543_CR30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/bja\/76.1.122","volume":"76","author":"MB Vroom","year":"1996","unstructured":"Vroom MB, Pfaffendorf M, van Wezel HB, van Zwieten PA (1996) Effect of phosphodiesterase inhibitors on human arteries in vitro. Br J Anaesth 76:122\u2013129","journal-title":"Br J Anaesth"},{"key":"1543_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/157016106775203072","volume":"4","author":"T Ueda","year":"2006","unstructured":"Ueda T, Mizushige K (2006) The effects of olprinone, a phosphodiesterase 3 inhibistor, on systemic and cerebral circulation. Curr Vasc Pharmacol 4:1\u20137","journal-title":"Curr Vasc Pharmacol"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-019-01543-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00380-019-01543-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-019-01543-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,20]],"date-time":"2020-12-20T00:27:38Z","timestamp":1608424058000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00380-019-01543-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,21]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["1543"],"URL":"https:\/\/doi.org\/10.1007\/s00380-019-01543-6","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,21]]},"assertion":[{"value":"8 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"TI received grant support from Bristol-Myers Squibb Bayer Healthcare, Medtronic Japan, Japan Lifeline and Daiichi Sankyo and lecture fees from Bayer Healthcare, Bristol-Myers Squibb, Pfizer, Daiichi Sankyo and Ono Pharmaceutical. The other authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}